Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 13/20 | 0.49 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.48 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.45 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | CMA1 | P23946 | 2/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8290087 | 1.00 | DPP4 (0.49) | DPP4KLK5ACEDPP8DPP9 | |
| SCHEMBL7852576 | 0.90 | DPP4 (0.61) | DPP4KLK5ACEDPP8DPP9 | |
| SCHEMBL8273836 | 0.88 | DPP4 (0.48) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL7852591 | 0.87 | DPP4 (0.49) | DPP4KLK5DPP8DPP9DPP7 | |
| SCHEMBL8373795 | 0.87 | DPP4 (0.49) | DPP4KLK5DPP8DPP9DPP7 | |
| SCHEMBL4955095 | 0.87 | DPP4 (0.51) | DPP4KLK5DPP8DPP9DPP7 | |
| SCHEMBL8289111 | 0.87 | DPP4 (0.51) | DPP4KLK5DPP8DPP9DPP7 | |
| SCHEMBL8290132 | 0.85 | DPP4 (0.51) | DPP4KLK5ACEDPP8DPP9 | |
| SCHEMBL8373777 | 0.84 | KLK5 (0.47) | DPP4KLK5ACEDPP8DPP9 | |
| SCHEMBL7858468 | 0.84 | KLK5 (0.47) | DPP4KLK5ACEDPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176838-A1 | Dpp-IV Inhibitors | SANTHERA PHARMACEUTICALS (DEUTSCHLAND) AG (DE) | 2008-07-24 | — | — | US | disclosed |
| US-20080027035-A1 | Dpp-Iv Inhibitors | GRAFFINITY PHARMACEUTICALS AG (DE) | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027035-A1 | Dpp-Iv Inhibitors | DPP4, DPP7, DPP3 | DPP4 1/4885KLK5 84/4885ACE 15/4885 |
| US-20080176838-A1 | Dpp-IV Inhibitors | DPP4, DPP9, DPP7 | DPP4 1/4885KLK5 1019/4885ACE 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.